Zhenghu Chen

Yangtze River Pharmaceutical Group (China)

Also affiliated with Shanghai University of Medicine and Health Sciences

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma”.

MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

Scientific Reports(2021)10.1038/s41598-021-82542-4

N/A

0DataRank · unranked

42 citations

Yan Shi, Roma H. Patel, Zhenghu Chen, Aayushi Shah, Rohit Srivastava +12 more

Author Correction: MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

Scientific Reports(2021)10.1038/s41598-021-98174-7

N/A

0DataRank · unranked

1 citations

Yan Shi, Roma H. Patel, Zhenghu Chen, Aayushi Shah, Rohit Srivastava +12 more

Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer

Molecular Therapy(2022)10.1016/j.ymthe.2022.02.004

N/A

0DataRank · unranked

24 citations

Zihua Zeng, Jianjun Qi, Zhenghu Chen, Xiaohui Liu, Youli Zu +1 more